NCT02844517已完成不适用
Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 10
- 主要终点
- The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.
研究概览
简要总结
The objective of the study is for clinical staff to gain experience using the proposed artificial pancreas system named inControl and the inControl Cloud and assess 24/7 in-home usability prior to initiating a large randomized controlled trial.
详细描述
Participation in this study will require 5 study visits over 2-4 weeks.
- Visit 1: screening/enrollment visit to assess study eligibility.
- Visit 2: continuous glucose monitor (CGM) training and initiation session based upon current or prior use of a CGM; if subject doesn't currently use a CGM, subject will be trained and may be asked to wear the CGM at home for 1 week.
- Visit 3: subjects will be taught how to use the study insulin pump.
- Visit 4: subjects will be trained on the use of inControl and wear it at home for 14 days.
- Visit 5: subjects will return study equipment and to complete questionnaire.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 14 Years 至 74 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year
- •Use of an insulin pump for at least 6 months with established parameters for basal rate(s), carbohydrate ratio(s) and insulin sensitivity factor(s) for at least 3 months.
- •Age 14.0 to <75.0 years
- •HbA1c level <10.5% at screening
- •For females, not currently known to be pregnant. If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study. Also, subjects who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
- •Have care partner committed to participating in all training activities, knowledgeable at all times of the participants location, and being present and available to provide assistance when the system is being used at night
- •Willingness, if using the closed-loop system, to stop closed-loop when taking acetaminophen and avoid closed-loop for at least 4 hours afterward
- •Willingness to suspend use of any personal CGM for the duration of the clinical trial once the study CGM is in use
- •Willingness to establish network connectivity on a daily basis either via local Wi-Fi network or via a study-provided cellular service
- •Investigator has confidence that the subject can successfully operate all study devices and is capable of adhering to the protocol
- •Currently using no insulins other than one of the following rapid-acting insulins at the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin glulisine (Apidra)
- •Total daily insulin dose (TDD) less than 100 U/day
排除标准
- •More than one episode of diabetic ketoacidosis (DKA) in the 6 months prior to enrollment
- •More than one episode of severe hypoglycemia involving seizure of loss of consciousness in the 6 months prior to enrollment
- •Medical need for chronic acetaminophen
- •Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and naturaceuticals).
- •Hemophilia or any other bleeding disorder
- •A condition, which in the opinion of the investigator or designee, would put the participant or study at risk
- •Participation in another pharmaceutical or device trial at the time of enrollment or during the study
- •Employed by, or having immediate family members employed by TypeZero Technologies, LLC
研究组 & 干预措施
Artificial Pancreas
Experimental
The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.
干预措施: Artificial Pancreas (Device)
结局指标
主要结局
The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.
时间窗: 2 weeks
次要结局
未报告次要终点
研究者
Stacey Anderson
Study Chair
University of Virginia
研究点 (10)
Loading locations...
相似试验
已完成
1 期
Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)Type 1 Diabetes MellitusNCT01472406Sansum Diabetes Research Institute12
已完成
不适用
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1Type1 Diabetes MellitusNCT02985866University of Virginia127
已完成
1 期
Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal InsulinType 1 Diabetes MellitusNCT01929798Sansum Diabetes Research Institute36
已完成
不适用
Artificial Pancreas in Pediatric Patients (PEDarPAN)Type 1 DiabetesNCT02620878University of Padova48
尚未招募
不适用
Efficacy and Safety of an Artificial-pancreas-like Learning-based Control in Type 1 Diabetes on Multiple Daily Injection TherapyDiabetes Mellitus, Type 1NCT06418464Peking University People's Hospital120